Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.25
Bid: 5.00
Ask: 5.50
Change: 0.00 (0.00%)
Spread: 0.50 (10.00%)
Open: 5.25
High: 5.25
Low: 5.00
Prev. Close: 5.25
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Avation loss narrows; Franchise Brands profit rises

Thu, 03rd Mar 2022 19:32

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Avation PLC - Singapore-based commercial passenger aircraft leasing company - For the six months ended December 31, pretax loss narrows to USD15.9 million from USD60.5 million, due to a much lower impairment loss on aircraft and credit losses. Revenue drops 6% year-on-year to USD57.9 million from USD61.3 million. Avation's aircraft fleet stands at 42, however fleet assets declines 7.0% year-on-year to USD1.00 billion as at December 31 from USD1.08 billion at the end of June.

----------

Franchise Brands PLC - Manchester-based owner of ChipsAway, Willow Pumps and Metro Rod brands - For 2021, pretax profit rises 57% year-on-year to GBP5.8 million from GBP3.7 million the year before, on revenue which grows 17% year-on-year to GBP57.7 million from GBP49.3 million, with double digit sales from Metro Rod and Metro Plumb, as well as a strong recovery from the B2C division. Declares final dividend of 0.9 pence per share, bringing total payout to 1.5p, up 36% from 1.1p. Looking ahead, reports strong start to 2022, with continued sales growth in B2B.

----------

Poolbeg Pharma PLC - London-based pharmaceutical company - For the period from incorporation on March 19 to December 31, posts pretax loss of GBP2.3 million and no revenue as the company continues to develop its severe influenza treatment POLB 001.

----------

Crystal Amber Fund Ltd - Guernsey-based investment company - As at December 31, net asset value per share increases 11% year-on-year to 143.19 pence from 128.99p. For the six month period, delivered NAV negative return of 0.8%, compared to a 4.7% positive return from the Numis Small Cap Index.

----------

JPMorgan Global Growth & Income PLC - invests in companies around the world - As at December 31, net asset value per share increases 6.1% year-on-year to 459.1 pence from 432.3p, while for the six month period, NAV total return is 8.2%, compared to a 7.7% return from the MSCI AC World Index.

----------

t42 IoT Tracking Solutions PLC - Jersey-based provider of tracking, security and monitoring solutions for containers and freight - For 2021, operating loss widens to USD2.7 million from USD1.8 million, on revenue which declines 16% year-on-year to USD4.2 million from USD5.0 million due to supply chain issues and a performance turnaround only taking place near the end of 2021.

----------

Allergy Therapeutics PLC - Sussex-based biotechnology firm focused on allergy vaccines - For the six months ended December 31, pretax profit drops 54% to GBP7.3 million from GBP15.8 million a year before, due to a rise in costs and a 10% year-on-year decline in revenue to GBP48.7 million from GBP54.0 million, due to the strategic streamlining of older products. Looking ahead, company has a strong outlook for the full financial year with operating profit on track to meet consensus expectations.

----------

Power Metal Resources PLC - London-based metals exploration company focused in North America, Africa and Australia - For the year ended September 30, pretax loss narrows to GBP623,000 from GBP1.4 million the year before, due to smaller impairment charges, and a slight rise in revenue to GBP37,000 from GBP9,000

----------

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
27 Nov 2018 13:12

Allergy Therapeutics Continues To Perform Well, Revenue Up "Strongly"

LONDON (Alliance News) - Allergy Therapeutics PLC said Tuesday it has continued to perform well, with revenue up "strongly" from the prior year and sales in line with market financial to

Read more
27 Nov 2018 10:05

Allergy Therapeutics boosted by strong German performance

(Sharecast News) - Biotechnology company Allergy Therapeutics has seen revenues increase throughout the first half of its trading year thanks to an improved market share for its allergy vaccines on the continent.

Read more
23 Oct 2018 16:11

BlackRock Lowers Allergy Therapeutics Stake Below Threshold (ALLISS)

LONDON (Alliance News) - Allergy Therapeutics PLC said Tuesday that BlackRock Inc lowered its stake in the company to below the 5% threshold.Prior to the deal, BlackRock held a 5.1% in the

Read more
26 Sep 2018 12:42

Allergy Therapeutics Interim Loss Widens But Germany Pushes Revenue Up

LONDON (Alliance News) - Allergy Therapeutics PLC on Wednesday said its loss widened in the first half of 2018, but revenue rose on strong performance in Germany and a strengthening of the company

Read more
19 Jul 2018 11:08

Allergy Therapeutics To Raise GBP11 Million Via Share Issue (ALLISS)

LONDON (Alliance News) - Allergy Therapeutics PLC said Thursday that it will raise up to GBP10.6 million via placing and subscription.The pharmaceutical company focused on allergy vaccines

Read more
29 May 2018 11:19

Allergy Therapeutics Reveals Good Results From Dust Mite Allergy Tests

LONDON (Alliance News) - Biotechnology firm Allergy Therapeutics PLC said it will present positive new data on its dust mite allergy treatment at a congress in Germany on Tuesday.Allergy is

Read more
21 May 2018 11:49

Allergy Therapeutics Reports Positive Results From Grass Pollen Study

LONDON (Alliance News) - Allergy Therapeutics PLC said Monday it saw positive results from its grass pollen allergy treatment phase II dose ranging study as it prepares to commence in phase III it

Read more
14 May 2018 12:24

Allergy Therapeutics Gets Positive Indications In Latest MCT Study

LONDON (Alliance News) - Biotechnology firm Allergy Therapeutics PLC on Monday said it has received positive new data in a study investigating its microcrystalline tyrosine-based results, it said,

Read more
16 Mar 2018 17:30

DIRECTOR DEALINGS: Allergy Therapeutics Non-Executive Lifts Stake

LONDON (Alliance News) - Pharmaceutical company Allergy Therapeutics PLC said Friday Non-Executive Director Tunde Otulana acquired shares on Thursday.Otulana acquired a

Read more
7 Mar 2018 13:42

Allergy Therapeutics Profit Falls On Costs As Pivotal Year Looms

LONDON (Alliance News) - Allergy Therapeutics PLC said Wednesday half year profit fell due to higher research and development costs, as the company prepares for 2018 clinical

Read more
14 Feb 2017 14:46

Allergy Therapeutics gets trial go-ahead in Spain

(ShareCast News) - Specialty pharmaceutical company Allergy Therapeutics announced on Tuesday that its Phase I clinical study investigating the safety and tolerability of Acarovac MPL received 'Clinical Trial Application' approval in Spain. The AIM-traded firm said it now expected the formulation to

Read more
14 Feb 2017 08:49

Allergy Therapeutics' House-Dust Mite Allergy Vaccine Trial Approved

Read more
2 Nov 2016 09:41

New broad patent strengthens Allergy Therapeutics portfolio

(ShareCast News) - Vaccine-focused pharmaceutical company Allergy Therapeutics announced on Wednesday that the European Patent Office has granted a broad technology patent relating to the its unique microcrystalline tyrosine depot adjuvant manufacturing process. The AIM-traded firm said the patent c

Read more
2 Nov 2016 09:29

Allergy Therapeutics Granted EU Patent For Microcrystalline Tyrosine

Read more
10 Oct 2016 11:59

Allergy Therapeutics examines potential of adjuvant portfolio

(ShareCast News) - Allergy Therapeutics will look into potential wider applications for its adjuvant technology after recent clinical research produced encouraging indications about both allergy vaccination and infectious disease applications. Microcrystalline tyrosine (MCT), an aluminium-free depot

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.